Pacira BioSciences' Share-based Compensation rose 5.65% to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.3 million, marking a year-over-year increase of 9.63%. This contributed to the annual value of $51.2 million for FY2024, which is 6.84% up from last year.
Pacira BioSciences' Share-based Compensation amounted to $14.0 million in Q3 2025, which was down 9.66% from $15.5 million recorded in Q2 2025.
Pacira BioSciences' Share-based Compensation's 5-year high stood at $15.5 million during Q2 2025, with a 5-year trough of $10.1 million in Q1 2021.
Its 3-year average for Share-based Compensation is $13.0 million, with a median of $12.5 million in 2023.
Its Share-based Compensation has fluctuated over the past 5 years, first decreased by 5.10% in 2023, then increased by 23.54% in 2025.
Over the past 5 years, Pacira BioSciences' Share-based Compensation (Quarterly) stood at $10.9 million in 2021, then climbed by 16.41% to $12.7 million in 2022, then fell by 2.03% to $12.4 million in 2023, then declined by 1.24% to $12.3 million in 2024, then increased by 5.65% to $14.0 million in 2025.
Its last three reported values are $14.0 million in Q3 2025, $15.5 million for Q2 2025, and $14.6 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value